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Platelet inhibition by clopidogrel plays an important role in the 
prevention of thromboembolic events after myocardial infarc-
tion (MI) and percutaneous coronary intervention (PCI).1,2 
However, treatment with clopidogrel is associated with a sig-
nificant risk of bleeding, which has been partially attributed to 
genetic predisposition, drug interactions, and other factors.3 
Clopidogrel is a prodrug that, after absorption, is extensively 
metabolized by two major hepatic enzyme systems, car-
boxylesterase 1 (CES1) and cytochrome P450 (CYP).4,5 The 
majority (85–95%) of ingested clopidogrel never enters the 
complex CYP-mediated bioactivation cascade due to substan-
tial CES1-mediated hydrolysis of the parent drug to the inactive 
clopidogrel carboxylic acid, and the remaining 5–15% of the 
clopidogrel dose is subject to metabolic activation via a two-
step oxidative process mediated by multiple CYP enzymes.4–6 In 
addition, CES1 is also involved in hydrolysis of both the inter-
mediate metabolite 2-oxo-clopidogrel and the 5-thiol clopi-
dogrel active metabolite (clopidogrel-AM). These multiple roles 
of CES1 suggest that it is a primary metabolic determinant of 
clopidogrel bioactivation.5–8
The majority of studies assessing the importance of genetic 
variants and drug–drug interactions (DDIs) in the clinical safety 
and efficacy of clopidogrel have focused on the CYP system, e.g., 
CYP2C19 gene variants, and the potential influence of cotreat-
ment with statins, proton pump inhibitors, and calcium channel 
blockers.3,9,10 Although significant variability is known to exist 
in the expression and activity of CES1, including CES1 single-
nucleotide polymorphisms associated with markedly impaired 
hydrolytic activity of CES1, only recently has there been docu-
mentation that these CES1 variants are associated with signifi-
cantly higher exposure to clopidogrel-AM and enhanced platelet 
inhibition in patients treated with clopidogrel.7,11
Angiotensin-converting enzyme inhibitors (ACEIs) are 
mainstay medications after MI, and most are thought to be sub-
strates for CES1.12,13 ACEIs are hence routinely coprescribed 
with clopidogrel, and we therefore hypothesized that ACEIs, 
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Clopidogrel is an oral antiplatelet prodrug, the majority of which is hydrolyzed to an inactive metabolite by 
hepatic carboxylesterase 1 (CES1). Most angiotensin-converting enzyme inhibitors (ACEIs) are also metabolized 
by this enzyme. We examined the effects of ACEIs on clopidogrel bioactivation in vitro and linked the results with 
a pharmacoepidemiological study. In vitro, ACEIs inhibited CES1-mediated hydrolysis of a model substrate, and 
trandolapril and enalapril increased formation of clopidogrel active metabolite. In 70,934 patients with myocardial 
infarction, hazard ratios for clinically significant bleeding in ACEI-treated patients cotreated with or without clopidogrel 
were 1.10 (95% confidence interval (CI): 0.97–1.25, P = 0.124) and 0.90 (95% CI: 0.81–0.99, P = 0.025), respectively, as 
compared with patients who did not receive ACEIs. This difference was statistically significant (P = 0.002). We conclude 
that cotreatment with selected ACEIs and clopidogrel may increase the risk of bleeding. Combination of in vitro and 
pharmacoepidemiological studies may be a useful paradigm for assessment of drug–drug interactions.
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when coadministered with clopidogrel, have a high likelihood 
of competing with clopidogrel for the catalytic site of CES1. 
This competition could lead to a shunting of a larger fraction 
of absorbed clopidogrel directly to CYP-mediated activation, 
ultimately increasing the systemic exposure to clopidogrel-AM, 
producing greater platelet inhibition and an increased risk of 
bleeding. To our knowledge, this potential DDI has not been 
examined previously, and large randomized clinical trials for 
such purposes would be extremely costly and are unlikely to 
be performed in the postmarketing period. Other prospec-
tive studies, e.g., of ex vivo platelet activation in healthy vol-
unteers receiving these drugs alone or in combination, could 
provide surrogate end points, but their clinical relevance might 
be open to question. In this context, a strategy was devised 
that links the results of targeted in vitro DDI studies to tar-
geted pharmacoepidemiological studies of large populations 
of real-world patients. Combining these two methodologies, 
which examine the DDI potential from opposite ends of the 
“spectrum” of DDI assessment and detection, may represent 
a useful study paradigm for assessment of the occurrence and 
clinical relevance of DDIs. Therefore, to potentially provide a 
proof of concept for this strategy, we investigated the effects of 
ACEIs on clopidogrel bioactivation in vitro, in tandem with an 
examination of the nationwide Danish registries to assess the 
effects of ACEIs on bleeding in patients with MI treated or not 
treated with clopidogrel.
RESULTS
In vitro substudy
The p-nitrophenyl acetate (PNPA) incubation study demon-
strated that the four tested ACEIs exhibited varying degrees 
of inhibitory effects on CES1-mediated PNPA hydrolysis 
following incubation with s9 fractions prepared from the 
CES1-transfected human embryonic kidney (HEK)-293 cells 
(Figure 1a). The calculated IC50 (concentration at which 
50% of enzymatic activity is inhibited) value of enalapril was 
447.6 ± 27.3 μmol/l, whereas 50% inhibition of PNPA hydrolysis 
was not achieved after incubation with the remaining ACEIs, 
even at the highest concentration tested (1,000 μmol/l). Further 
in vitro studies using human liver s9 fractions were conducted 
to evaluate the effect of ACEIs on the bioactivation of clopi-
dogrel (Figure 1b,c). Among the tested ACEIs, trandolapril and 
enalapril were found to significantly increase the formation of 
2-oxo-clopidogrel and clopidogrel-AM. In addition, coincu-
bation of clopidogrel with ramipril and perindopril enhanced 
the formation of clopidogrel-AM, although the increase was 
not statistically significant under the current experimental 
conditions. Bis(4-nitrophenyl) phosphate (BNPP), a potent 
CES1 inhibitor, was included in the study as a positive control. 
As expected, BNPP significantly increased the production of 
2-oxo-clopidogrel and clopidogrel-AM via inhibition of CES1-
mediated hydrolysis.
Epidemiological substudy
Study population. We identified a total of 97,528 patients with 
a first-time MI in the period 2000–2010. Of these, 25,001 
died or had an event within the 7-day qualifying period and 
1,593 were younger than 30 years. Therefore, a total of 70,934 
were enrolled in the study. In this population, 29,043 (40.9%) 
received clopidogrel within 7 days of discharge, and of these, 
9,069 (31.2%) received ACEIs at baseline. Of the remaining 
41,891 (59.1%) who did not receive clopidogrel, 6,593 (15.7%) 
received ACEIs. Baseline characteristics of the study popu-
lation at time of inclusion are shown in Table 1. In general, 
subjects who did not receive clopidogrel were in lower income 
groups, had more comorbidity, and received more concomi-
tant medications, except for β-blockers, aspirin, and statins. 
A larger percentage (63.5%) of patients treated with PCI 
received clopidogrel, as compared with the group that did not 
undergo PCI (36.3%). Independent of clopidogrel treatment, 
individuals treated with ACEIs had higher comorbidity and 
received more concomitant medication at baseline. During 
the follow-up period, 4,799 clopidogrel-treated subjects and 
11,259 patients without clopidogrel treatment changed status 
from no ACEI treatment to ACEI treatment. The distribution 
of individual ACEIs used in the study population is shown in 
Table 2. Of note, ramipril, enalapril, trandolapril, and per-
indopril comprised >95% of the ACEIs used, with enalapril 
and trandolapril accounting for almost 50% of all ACEIs used 
during the study period.
Bleeding, cardiovascular death, MI, stroke, and all-cause  mortality 
 during 1 year of follow-up. Crude incidence rates of study end 
points per 100 patient-years in subjects who received clopi-
dogrel or ACEIs as single therapies or in combination, 
after first-time MI during 1 year of follow-up are shown in 
Supplementary Table S1 online. As shown in Table 3, in the 
Study Highlights
WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC?
 3 Clopidogrel is a prodrug, the majority of which is hydrolyzed 
to an inactive metabolite by hepatic CES1. This enzyme also 
activates most ACEIs.
WHAT QUESTION DID THIS STUDY ADDRESS?
 3 We examined whether ACEIs increased clopidogrel bioac-
tivation in vitro and whether cotreatment with ACEIs and 
clopidogrel was associated with increased risk of clinically 
significant bleeding in a nationwide pharmacoepidemio-
logical study.
WHAT THIS STUDY ADDS TO OUR KNOWLEDGE
 3 ACEIs increased formation of clopidogrel active metabolite 
in vitro, and cotreatment with these two agents was associ-
ated with increased risk of bleeding in patients after MI.
HOW THIS MIGHT CHANGE CLINICAL PHARMACOLOGY 
AND THERAPEUTICS
 3 The results suggest that increased risk of clinically significant 
bleeding should be considered in patients cotreated with 
clopidogrel and ACEIs. The combination of targeted in vitro 
investigations and pharmacoepidemiological studies may 
represent a useful paradigm for assessment of DDIs.
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adjusted Cox proportional hazard analyses, treatment with 
ACEIs in clopidogrel-treated patients was associated with a 
nominally increased risk of bleeding (hazard ratio (HR): 1.10; 
95% confidence interval (CI): 0.97–1.25; P = 0.124), whereas 
in the absence of clopidogrel treatment, ACEIs were associ-
ated with a significantly decreased risk of bleeding (HR: 0.90; 
95% CI: 0.81–0.99; P = 0.025). The difference between these 
two HRs, expressed as the hazard rate ratio (HRR), was statis-
tically significant (HRR: 1.27; 95% CI: 1.09–1.49; P = 0.002), 
indicating an effect modification of concomitant treatment 
with ACEIs and clopidogrel on bleeding. This association was 
reproducible in all examined subgroups (Figure 2). As shown 
in Table 3 and Figure 3, similar results were found for the 
secondary end points of cardiovascular death (HR: 1.29; 95% 
CI: 1.14–1.44; P < 0.001), all-cause mortality (HR: 1.14; 95% 
CI: 1.04–1.25; P < 0.001), and the composite of cardiovascular 
death, MI, or stroke (HR: 1.12; 95% CI: 1.06–1.19; P < 0.001), 
although no differences in risk were found for MI (HRR: 0.95; 
95% CI: 0.87–1.03; P = 0.223) or stroke (HRR: 1.10; 95% CI: 
0.89–1.36; P = 0.376). When analyses of bleeding were done on 
the basis of individual ACEIs, the interaction with clopidogrel 
tended to be absent in the group of patients receiving captopril 
and lisinopril, the only two ACEIs that are not metabolized by 
CES1 (Figure 4). In addition, we found no interaction between 
ACEI treatment and any of the explanatory covariates for the 
primary end point of bleeding.
DISCUSSION
The current proof-of-concept study, with a combination of in 
vitro and pharmacoepidemiological investigations, provided two 
important new insights. First, the in vitro assessments showed 
that all tested ACEIs increased the bioactivation of clopidogrel 
in human liver s9 fractions and that significantly increased con-
centrations of clopidogrel-AM were achieved following coincu-
bation of clopidogrel with trandolapril and enalapril. Second, 
the clinical importance of these in vitro findings was apparently 
borne out in a nationwide pharmacoepidemiological study of 
patients discharged after first-time MI and followed for 1 year, 
in which treatment with ACEIs was associated with signifi-
cantly increased risk of clinically important bleeding in patients 
receiving clopidogrel. Cotreatment with ACEIs and clopidogrel 
was also linked to increased risk of cardiovascular death and 
all-cause mortality, and this association with increased risk 
of bleeding was consistent in all examined subgroups. To our 
knowledge, these data, obtained with the use of an approach that 
combined in vitro and pharmacoepidemiological investigations, 
are the first to suggest a clinically significant ACEI–clopidogrel 
interaction. The in vitro demonstration of the CES1-centered 
mechanism of interaction provides a compelling rationale 
for the pharmacoepidemiological results, and this combined 
approach may represent a useful paradigm for evaluation of 
suspected DDIs in the postmarketing period, which might be 
applied to various drug combinations in use.
Figure 1  Clopidogrel bioactivation in vitro. (a) Effects of the angiotensin-converting enzyme inhibitors (ACEIs) trandolapril, enalapril, ramipril, and perindopril 
on carboxylesterase 1 (CES1) activity, determined by p-nitrophenyl acetate (PNPA) hydrolysis in CES1-transfected HEK-293 cells and formation of (b) 2-oxo-
clopidogrel and (c) clopidogrel-AM (active metabolite) after incubation of clopidogrel with human liver s9 fractions. Data are presented as means ± SD (n = 3). 
BNPP, bis(4-nitrophenyl) phosphate; HEK, human embryonic kidney. *P < 0.05 and ***P < 0.001 vs. control.
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Clopidogrel is a prodrug undergoing substantial biotrans-
formation catalyzed by hepatic CES1, which is responsible for 
80–95% of the total hydrolytic activity in the human liver.7 CES1 
catalyzes the hydrolysis of ester- and amide-containing endog-
enous substrates, toxins, and various drugs to their respective 
free acids, and evolving evidence suggests that the importance 
of CES1 in human drug metabolism may have been somewhat 
overlooked relative to CYP enzymes.5,14,15 After administration 
of the prodrug, the majority of absorbed clopidogrel is rapidly 
hydrolyzed by CES1 to the inactive carboxylic acid metabolite, 
and only the remaining 5–15% is subjected to CYP-mediated 
bioactivation.6,14 Furthermore, CES1 hydrolyzes a proportion of 
Table 1 Baseline characteristics of patients with first-time myocardial infarction who survived 7 days from discharge
Clopidogrel (n = 29,043) no clopidogrel (n = 41,891)
no ACEI (n = 19,974) ACEI (n = 9,069) no ACEI (n = 35,298) ACEI (n = 6,593)
n = 15,175a n = 13,868a n = 24,039a n = 17,852a
Age (mean (SD) years) 66.0 (±13.2) 65.7 (±13.0) 70.8 (±13.7) 71.8 (±12.5)
Men (%) 13,375 (67.0) 6,262 (69.1) 20,417 (57.8) 3,905 (69.2)
  Age (mean (SD) years) 63.9 (±12.5) 63.6 (±12.4) 67.7 (±13.4) 69.2 (±12.3)
Women (%) 6,599 (33.0) 2,807 (31.0) 14,881 (42.2) 2,688 (40.8)
  Age (mean (SD) years) 70.4 (±13.4) 70.4 (±13.1) 75.0 (±13.0) 75.8 (±11.6)
Year of inclusion
  2000–2004 (%) 6,282 (31.4) 2,929 (32.2) 20,406 (56.8) 4,795 (72.8)
  2005–2010 (%) 13,629 (68.6) 6,140 (67.8) 14,892 (43.2) 1,798 (27.2)
Income group
  Income group 0 – 2 (%) 6,142 (46.4) 4,164 (46.0) 21,919 (62.5) 4,279 (65.0)
  Income group 3 – 4 (%) 10,694 (53.6) 4,894 (54.1) 13,186 (37.6) 2,305 (35.1)
Missing values 44 202
PCI (%) 5,607 (28.1) 2,048 (22.6) 4,086 (11.6) 316 (4.8)
Comorbidity
  Shock (%) 122 (0.6) 58 (0.6) 703 (2.0) 62 (0.9)
  DM with complications (%) 667 (3.3) 279 (3.1) 1,979 (5.6) 374 (5.7)
  Peptic ulcer (%) 178 (0.9) 63 (0.7) 784 (2.2) 99 (1.5)
  Pulmonary edema (%) 96 (0.5) 57 (0.6) 441 (1.3) 123 (1.9)
  Peripheral vascular disease (%) 381 (1.9) 127 (1.4) 1,143 (3.2) 160 (2.4)
  Cerebrovascular disease (%) 597 (3.0) 241 (2.7) 2,266 (6.4) 318 (4.8)
  Cancer (%) 366 (1.8) 124 (1.4) 1,356 (3.8) 168 (2.6)
  Cardiac dysrhythmia (%) 1,460 (7.3) 78 (7.9) 5,002 (14.2) 896 (13.6)
  Acute renal failure (%) 116 (0.6) 21 (0.2) 620 (1.8) 36 (0.6)
  Chronic renal failure (%) 289 (1.5) 43 (0.5) 798 (2.3) 67 (1.0)
Concomitant medication
  Loop diuretic (%) 2,028 (10.2) 2,011 (22.2) 4,017 (11.4) 219 (42.8)
  Thiazide (%) 622 (3.3) 455 (5.0) 824 (2.3) 384 (5.8)
  Spironolactone (%) 373 (1.9) 594 (6.6) 807 (2.3) 965 (14.6)
  Aspirin (%) 14,284 (71.5) 7,383 (81.4) 10,063 (28.5) 4,319 (65.5)
  Vitamin K antagonist (%) 278 (1.4) 250 (2.8) 694 (2.0) 563 (8.5)
  Statin (%) 14,299 (71.6) 7,440 (82.0) 6,300 (17.9) 2,959 (44.9)
  β-Blocker (%) 14,584 (73.0) 7,495 (82.6) 10,795 (30.6) 4,660 (70.7)
  CCB (%) 1,517 (7.6) 510 (5.6) 1,787 (5.1) 518 (7.9)
  Digoxin (%) 389 (2.0) 272 (3.0) 1,050 (3.0) 600 (9.1)
  Glucose-lowering drug (%) 566 (2.8) 441 (4.9) 747 (2.1) 423 (6.4)
ACEI, angiotensin-converting enzyme inhibitor; CCB, calcium channel blocker; DM, diabetes mellitus; PCI, percutaneous coronary intervention.
aNumber of patients 1 year after inclusion.
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a 2-oxo-clopidogrel intermediate in the complex CYP oxidation 
scheme, as well as hydrolyzing the unstable 5-thiol clopidogrel-
AM itself.7,8 In addition to its role in inactivation of clopidogrel, 
CES1 is involved in metabolism of other drugs, and previous 
interest has focused on methylphenidate, oseltamivir, and 
ACEIs.14,15 Specifically, most ACEIs are esterified prodrugs that 
are likewise activated by hydrolysis, and CES1 has conclusively 
been shown to govern hydrolysis of trandolapril; accumulating 
evidence has suggested that CES1 is responsible for activation 
of most other ACEIs, apart from captopril and lisinopril, which 
are devoid of ester bonds.12,13,15–19
Platelet inhibition in response to clopidogrel is highly vari-
able, and clopidogrel resistance is associated with ischemic 
events, including stent thrombosis after PCI, whereas increased 
exposure to clopidogrel can result in bleeding.20,21 Hitherto-
identified genetic variants (e.g., CYP2C19*2) and demographic 
and/or clinical factors influencing clopidogrel disposition 
and pharmacodynamics explain only a small part of the vari-
ability in the response to clopidogrel.9,22,23 Recently, however, 
single-nucleotide polymorphisms in CES1 were found to have 
marked effects on clopidogrel bioactivation. Specifically, in vitro 
studies have documented that the catalytic activity of a CES1 
p.Gly143Glu variant was essentially abolished in terms of cata-
lyzing the hydrolysis of clopidogrel and 2-oxo-clopidogrel.12 
Furthermore, subjects with this variant were found to have 
high on-treatment levels of the clopidogrel-AM and increased 
platelet inhibition as assessed by platelet function assays.11 This 
CES1 gene variant has previously been associated with loss of 
CES1’s ability to hydrolyze ACEIs (i.e., trandolapril).12 Because 
alterations of CES1 activity clearly influence clopidogrel bioac-
tivation and platelet inhibitory effects, and because our in vitro 
results in the HEK-293 cell model system support the hypoth-
esis that ACEIs inhibits CES1 catalytic activity (Figure 1a), we 
hypothesized that coincubation of ACEIs and clopidogrel could 
increase formation of clopidogrel-AM in human liver s9 frac-
tions. Indeed, this was found to be the case (Figure 1b,c), setting 
the stage for our pharmacoepidemiological substudy, in which 
cotreatment with the two agents was associated with increased 
risk of clinically important bleeding.
In the current study, the largest increase in risk of bleed-
ing associated with the ACEI–clopidogrel combination was 
observed in patients included before 2004 and in those who 
Table 2 Distribution of ACEIs at baseline and after 1 year
ACEI ATC code
Baseline 1 year
Clopidogrel (n = 9,069) no clopidogrel (n = 6,593) Clopidogrel (n = 13,868) no clopidogrel (n = 17,852)
Ramipril C09AA05 4,224 (46.6) 2,354 (35.7) 5,950 (42.9) 6,430 (36.0)
Enalapril C09AA02 2,639 (29.1) 1,354 (20.5) 4,589 (33.1) 4,880 (27.3)
Trandolapril C09AA10 1,291 (14.2) 1,909 (29.0) 1,792 (12.9) 3,981 (22.3)
Perindopril C09AA04 774 (8.5) 792 (12.0) 1,194 (8.6) 2,009 (11.3)
Lisinopril C09AA03 123 (1.4) 107 (1.6) 292 (2.1) 333 (1.9)
Captopril C09AA01 17 (0.2) 66 (1.0) 40 (0.3) 181 (1.0)
Fosinopril C09AA09 1 (0.01) 4 (0.1) 2 (0.01) 8 (0.04)
Quinapril C09AA06 0 7 (0.1) 8 (0.1) 27 (0.2)
Benazepril C09AA07 0 0 1 (0.01) 3 (0.02)
Data are given as n (%).
ACEI, angiotensin-converting enzyme inhibitor; ATC, Anatomical Therapeutic Chemical Classification System.
Table 3 Risk associated with ACEIs and clopidogrel as single therapies and in combination
Clopidogrel (n = 29043) no clopidogrel (n = 41891)
likelihood for difference with 
ACEI treatment
no ACEI ACEI no ACEI ACEI
hr hr (CI) P value hr hr (CI) P value hrr (CI) P value*
Bleeding 1.00 1.10 (0.97–1.25) 0.124 1.00 0.90 (0.81–0.99) 0.025 1.27 (1.09–1.49) 0.002
MI, stroke, or CV death 1.00 1.12 (1.06–1.19) <0.001 1.00 1.03 (0.99–1.07) 0.162 1.09 (1.02–1.17) 0.014
MI 1.00 1.11 (1.04–1.20) 0.003 1.00 1.19 (1.13–1.25) <0.001 0.95 (0.87–1.03) 0.223
Stroke 1.00 1.23 (1.02–1.49) 0.029 1.00 1.14 (1.02–1.26) 0.021 1.10 (0.89–1.36) 0.376
CV death 1.00 1.29 (1.14–1.44) <0.001 1.00 0.85 (0.80–0.90) <0.001 1.49 (1.32–1.70) <0.001
All-cause mortality 1.00 1.14 (1.04–1.25) 0.007 1.00 0.81 (0.77–0.85) <0.001 1.42 (1.28–1.57) <0.001
Results from Cox proportional hazard models adjusted for age, gender, percutaneous coronary intervention, income, concomitant medication, and comorbidity.
ACEI, angiotensin-converting enzyme inhibitor; CI, 95% confidence interval; CV, cardiovascular; HR, hazard ratio; HRR, hazard rate ratio; MI, myocardial infarction.
*P value for interaction between ACEIs and clopidogrel.
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underwent PCI (Figure 2). Before 2004, treatment with clopi-
dogrel after MI was not firmly established in the Danish clini-
cal guidelines, and during this period, there was probably less 
difference in confounding variables between patients with vs. 
those without clopidogrel; i.e., the more pronounced bleeding 
signal here is arguably supportive of our hypothesis. Bleeding 
represents the most common complication after PCI, and in 
accord with our current findings, these patients were expected to 
bleed more with increased exposure to clopidogrel. On the other 
hand, absence of increased bleeding in patients with diabetes 
who are treated concurrently with ACEIs and clopidogrel is in 
agreement with the increased prevalence of high platelet reactiv-
ity in these subjects; i.e., increased exposure to clopidogrel may 
not be sufficient to cause significant bleeding.24,25 In addition to 
increased risk of bleeding, the ACEI–clopidogrel combination 
was also associated with higher risk of cardiovascular death, all-
cause mortality, and a composite of cardiovascular death, MI, 
or stroke, and the last was primarily driven by cardiovascular 
Figure 2  Risk of bleeding in selected subpopulations. Results from adjusted multivariate Cox proportional hazard analyses. Error bars illustrate 95% confidence 
intervals. Hazard rate ratios (HRRs) illustrate difference in risk for treatment with angiotensin-converting enzyme inhibitors (ACEIs) between the groups treated 
with or without clopidogrel. HR, hazard ratio; PCI, percutaneous coronary intervention; VKA, vitamin K antagonist.
0.4 0.5 1.0
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1.5 2.0 0.4 0.5 1.0
HR
1.5 2.0 0.4 0.5 1.0
HRR
1.5 2.0
Figure 3  Risk of bleeding and secondary study outcomes. Results from adjusted multivariate Cox proportional hazard analyses. Error bars illustrate 95% 
confidence intervals. Hazard rate ratios (HRRs) illustrate difference in risk for treatment with angiotensin-converting enzyme inhibitors (ACEIs) between the 
groups with or without clopidogrel. CV, cardiovascular; HR, hazard ratio; IR, incidence rate; MI, myocardial infarction. *Crude IRs per 100 patient-years.
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deaths (Table 3; Figure 2). Although increased risk of ischemic 
events in the face of more bleeding with the drug combination 
would seem counterintuitive, it is well established that bleeding 
in post-MI patients is associated with death, stroke, and MI due 
to complications triggered by the bleeding itself and probable 
discontinuation of antithrombotic agents in the case of clini-
cally significant bleeding, as well as secondary increased risk of 
ischemic events.
As indicated above, the significant interindividual variability 
of CES1 activity is defined, in part, by variation of the CES1 gene. 
This gene is located on chromosome 16, and different structural 
haplotypes and sequence variants have been reported, with fre-
quencies being dependent on the ethnic background.26,27 The 
minor allele frequency of p.Gly143Glu was first determined to 
be 3.7, 4.3, 2.0, and 0% in white, black, Hispanic, and Asian 
populations, respectively, whereas frequencies of 0.6 and 0.85% 
were recently reported in an Amish population and US patients 
with coronary artery disease, respectively.11,28 Subjects with 
p.Gly143Glu or other CES1 variants are probably prone to bleed-
ing when treated with clopidogrel, irrespective of ACEI cotreat-
ment,6,11 but because of their relatively low prevalence, these 
variants are unlikely to have considerably skewed our results.
In addition to clopidogrel and ACEIs, other drugs with 
cardiovascular indications (e.g., dabigatran, simvastatin, and 
carvedilol) and various other medications (including meth-
ylphenidate, oseltamivir, flumazenil, mycophenolate mofetil, 
oxybutynin, and rufinamide) are also hydrolyzed by CES1, but 
as yet, potential DDIs involving combinations of these agents 
have not been assessed or reported.14,15,29–32 Importantly, aspi-
rin and newer platelet adenosine diphosphate receptor antago-
nists, including prasugrel and ticagrelor, are not metabolized by 
CES1 (aspirin and prasugrel are hydrolyzed by CES2, a distinct 
CES predominantly present in the intestine, and ticagrelor is 
not a prodrug) and are therefore not subject to the DDI mecha-
nism described above.5,6,33 The current results therefore raise 
the intriguing possibility that the relative increase in bleeding 
risk observed with prasugrel and ticagrelor in randomized trials 
that established improved efficacy of these agents as compared 
with clopidogrel in patients with acute coronary syndromes may 
have been even higher in absence of the large representation of 
individuals treated with ACEIs in these studies.34,35
Limitations
In vitro studies cannot accurately simulate in vivo conditions. 
A relatively high concentration of clopidogrel (20 μmol/l), 
which is substantially greater than what can be achieved in vivo, 
was used in the current study in order to produce measurable 
clopidogrel-AM in the in vitro system. However, such high sub-
strate concentration may have attenuated the inhibitory effect 
of ACEIs on CES1 in the current study. Therefore, it is possible 
that the CES1-mediated DDI between ACEIs and clopidogrel 
can be more significant in vivo than that observed in the in vitro 
study. Epidemiological observational studies are inherently at 
risk of unmeasured confounders and do not allow for causal 
conclusions. Indeed, there were baseline differences between our 
patient groups. Importantly, by using the combined data from 
patients with vs. without clopidogrel and treated (or not) with 
ACEIs, our statistical model also provided adjustment for con-
founders related to treatment with ACEIs and thereby allowed 
for estimation of the HRR for interaction between ACEIs and 
clopidogrel, i.e., the effect modification on bleeding that was 
most likely to be the result of the DDI. Notwithstanding sta-
tistical adjustments, however, unmeasured confounders may 
have affected these groups differently, and controls treated with 
prasugrel or ticagrelor may have provided further insights. Only 
bleedings that require hospitalization or fatal bleedings are regis-
tered in the Danish registries, and we cannot account for minor 
bleeding events. Baseline medication was evaluated by retrieved 
prescriptions within 7 days after discharge. Therefore, we did not 
consider alterations in medication during the year of follow–up, 
Figure 4  Risk of bleeding according to individual angiotensin-converting enzyme inhibitors (ACEIs) and clopidogrel treatment. Results from adjusted time-
dependent Cox proportional hazard analyses. Error bars illustrate 95% confidence intervals. Hazard rate ratios (HRRs) illustrate difference in bleeding risk for 
treatment with ACEIs between the groups with and without clopidogrel. HR, hazard ratio. P values for the difference between patients treated or not treated 
with clopidogrel were 0.002, 0.004, 0.101, 0.159, 0.373, and 0.943 for all ACEIs, ramipril, enalapril, trandolapril, perindopril, and captopril+lisinopril, respectively.
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except for use of ACEIs, which was assessed in a time-depend-
ent manner. In our main analyses, all ACEIs were considered 
together, although captopril and lisinopril are not metabolized 
by CES1.12,15–19 However, these two ACEIs comprised <5% of 
ACEIs used in the study and are therefore unlikely to have sig-
nificantly diluted the results (Table 2). Although the analyses 
applied to the individual ACEIs had reduced statistical power, 
the increased risk of bleeding associated with other examined 
ACEIs tended to be absent with captopril and lisinopril, which is 
in agreement with our study hypothesis (Figure 4). In addition, 
the influences of other drugs that have been proposed to mod-
ify clopidogrel efficacy and safety as a result of CYP-mediated 
interactions, e.g., selected statins, proton pump inhibitors, and 
calcium channel blockers, were not included as part of the cur-
rent analyses.9,13,15,29
Conclusions
To our knowledge, this is the first report to document an ACEI–
clopidogrel interaction. We found that, in vitro, coincubation 
with ACEIs increased clopidogrel bioactivation, and concomi-
tant treatment with ACEIs in patients who received clopidogrel 
after first-time MI was associated with increased risk of clinically 
important bleeding. The results raise concerns about concomi-
tant treatment with clopidogrel and ACEIs. The dual in vitro and 
pharmacoepidemiological approach may prove to be a useful 
study paradigm for assessment of suspected DDIs.
METHODS
In vitro substudy
Materials. Enalapril maleate, perindopril erbumine, moexipril hydrochlo-
ride, PNPA, the derivatizing agent 2-bromo-3′-methoxyacetophenone 
(MPB), and the CES1 inhibitor BNPP were purchased from Sigma-
Aldrich (St Louis, MO). p-Nitrophenol was obtained from TCI Amer-
ica (Portland, OR). Fosinopril sodium salt, ramipril, S-(+)-clopidogrel, 
2-oxo-clopidogrel, MPB-derivatized clopidogrel active metabolites (cis-
clopidogrel thiol metabolite and clopidogrel-AM), and the internal stand-
ard d4-clopidogrel carboxylate were from Toronto Research Chemicals 
(Toronto, ON, Canada). Pooled human liver s9 fraction (HLS9) and the 
RapidStart nicotinamide adenine dinucleotide phosphate (NADPH)
Regenerating System were purchased from XenoTech (Lenexa, KS). All 
other chemicals and reagents were of the highest analytical grade com-
mercially available.
Inhibitory effect of ACEIs on CES1-mediated PNPA hydrolysis. The model 
CES1 substrate PNPA and the HEK-293 cells stably expressing wild-type 
CES1—and no other major drug-metabolizing enzymes, including CYP 
enzymes—were used to assess the potential inhibitory effects of trandola-
pril, enalapril, ramipril, and perindopril on CES1 activity according to 
methods described previously.12,28 The final concentrations of the wild-
type CES1 cell s9 proteins and PNPA were 25 μg/ml and 100 μmol/l, 
respectively. The final concentrations of each tested ACEI ranged from 0 
to 1,000 μmol/l. The reaction mixtures contained various concentrations 
of dimethyl sulfoxide or methanol to improve solubility of ACEIs. Poten-
tial effects of the organic solvents on CES1 activity were controlled for by 
including vehicle controls. All experiments were carried out in triplicate.
Influence of ACEIs on clopidogrel activation in human liver s9 fractions. 
Pooled human liver s9 fractions were preincubated with the RapidStart 
NADPH Regenerating System (1 mmol/l yeast glucose-6-phosphate 
dehydrogenase, 1 mmol/l nicotinamide adenine dinucleotide phos-
phate, and 5 mmol/l glucose-6-phosphate) in the absence or presence 
of trandolapril, enalapril, ramipril, perindopril, and the known CES1 
inhibitor BNPP at 37 °C for 10 min. The reaction was initiated by adding 
the substrate clopidogrel. The final concentrations of the liver s9 frac-
tions and clopidogrel in the reaction system were 2 mg/ml and 20 µmol/l, 
respectively. The concentration of all tested ACEIs was 50 µmol/l, and the 
concentration of BNPP was 10 µmol/l. The final volume of the reaction 
system was 100 µl. The incubation time was 2 h, which was based on 
our previous studies that indicated that the maximum concentrations of 
formed clopidogrel-AM were achieved around 2 h following the initiation 
of incubation.7 The reaction was terminated by adding a twofold volume 
of acetonitrile containing the internal standard d4-clopidogrel carboxy-
late (50 ng/ml) and the derivatizing reagent MPB (5 mmol/l). MPB was 
used to form the stable MPB derivative of unstable clopidogrel-AM to 
facilitate analysis. The mixtures were left undisturbed at room tempera-
ture for 10 min to allow the derivatization reaction to be completed.36,37 
Samples were then centrifuged at 17,000 ×g at 4 °C for 20 min to remove 
precipitated proteins. The resulting supernatant was collected for liquid 
chromatography–tandem mass spectrometry analysis. The concentra-
tions of 2-oxo-clopidogrel and clopidogrel-AM were determined by a 
validated liquid chromatography–tandem mass spectrometry assay 
described previously.7
Pharmacoepidemiological substudy
The Danish Registries. As a data source, we used the Danish nationwide 
administrative registries. In Denmark, each citizen has a unique and per-
manent civil registration number that enables individual-level linkage 
of information from nationwide administrative registries. The National 
Patient Registry holds information on all admissions to Danish hospi-
tals since 1978 according to the International Classification of Diseases 
(ICD) codes.38 Information on all prescriptions dispensed from Danish 
pharmacies since 1995 is enumerated in the Danish Registry of Medicinal 
Product Statistics (prescription registry) according to the international 
Anatomical Therapeutic Chemical Classification System.39 Primary 
and contributing causes of death are registered in the National Causes of 
Death Registry. Information on birth date, vital statistics, gender, annual 
income, and migration were obtained from the Central Person Registry.
Study population and outcomes. All patients ≥30 years of age hospitalized 
with a first-time MI in the period 2000–2010 were identified from the 
National Patient Registry. Treatments with clopidogrel (B01AC04) and 
ACEIs (C09A) were determined by prescription claims within 7 days after 
discharge. Previous studies have documented that adherence to clopi-
dogrel is high in this population, with 1-year prescription continuation 
rates of 89% after 2004.40 ACEIs were divided into the individual agents 
marketed in Denmark during the study period, i.e., captopril (C09AA01), 
enalapril (C09AA02), lisinopril (C09AA03), perindopril (C09AA04), 
ramipril (C09AA05), quinapril (C09AA06), benazepril (C09AA07), fos-
inopril (C09AA09), and trandolapril (C09AA10). Data on individual drug 
doses were not available in the current data set. To avoid immortal time 
bias, only patients who survived without experiencing a study outcome 
the first 7 days after discharge were included in the study. Patients who 
permanently left the country within the study period were censored at 
time of emigration. The population was followed for 1 year after discharge.
The primary outcome of the study was clinically significant bleeding, 
including bleeding requiring hospitalization and fatal bleeding identi-
fied through the National Causes of Death Register, i.e., cerebral bleed-
ing (ICD codes I60–62, S06.4–06.6), bleeding from the respiratory tract 
(J94.2, R04), gastrointestinal bleeding (K25.0, K25.2, K25.4, K26.0, K26.2, 
K26.4, K27.0, K27.2, K28.0, K28.2, K92.0–92.2), and bleeding from the 
urinary tract (R31), as defined by either first admission with a diagnosis 
of nonfatal bleeding or as death from bleeding.41 Hospitalization due to 
bleeding has recently been validated for use in registry studies with posi-
tive predictive diagnostic values between 89 and 99%.42 Hospitalizations 
due to nonfatal bleedings—but that ended with death within a week after 
admission—were considered fatal bleedings. Secondary outcomes were 
a composite of cardiovascular death (I00–I99), hospitalization for recur-
rent MI (I21–I22), or stroke (I63–I66)—the individual components of the 
combined end point—and all-cause mortality. The MI and stroke diag-
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noses have previously been validated in the National Patient Registry.43,44 
For patients included in the study who experienced more than one of the 
above-mentioned adverse events, only the first event that occurred was 
considered in the data analysis.
Comorbidity, concomitant medication, and socioeconomic status. A comor-
bidity index was defined by the use of diagnoses at discharge after the 
index MI, as described in the Ontario acute MI mortality prediction 
rules.45 We further enhanced the power of this index by adding discharge 
diagnoses from the year before the index MI, as previously described.45,46 
We also obtained information on claimed prescriptions up to 7 days after 
discharge for other medications (Table 1). Moreover, we divided patients 
into five socioeconomic classes using the individual average annual gross 
income during the 5-year period before study inclusion.
Statistical analyses. All in vitro data are presented as means ± SDs. In 
the PNPA hydrolysis study, IC50 values were estimated by fitting the 
inhibition data to sigmoidal dose–response equations using GraphPad 
Prism 6.0 software (GraphPad Software, San Diego, CA). The differences 
between the ACEI-treated and control groups were analyzed using one-
way analysis of variance. In the epidemiological study, comparisons of 
baseline characteristics, including continuous and categorical variables, 
were made using χ2 test and Students t-test, respectively. Treatment with 
ACEIs was included in the analyses as a time-dependent variable. HRs 
for outcome variables, as well as likelihood for difference of outcome 
with ACEI treatment, expressed as HRRs, were determined from Cox 
proportional hazard models. These models were adjusted for age, gen-
der, calendar year, concomitant medication, comorbidity, income, and 
PCI. Furthermore, we performed analyses on selected subgroups. In all 
analyses, P < 0.05 was considered statistically significant.
Ethics. Ethical approval is not required for retrospective registry studies in 
Denmark. The study was approved by the Danish Data Protection Agency 
(2007-58-0015/GEH-2014-012 I-Suite 02720). The work was carried out 
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ted to Biomedical Journals (http://www.icmje.org).
SUPPLEMENTARY MATERIAL is linked to the online version of the paper at 
http://www.nature.com/cpt
ACKNOWLEDGMENTS
The current study is part of the Individualized Drug Therapy Based on 
Pharmacogenomics: Focus on Carboxylesterase 1 (INDICES) project, which 
was funded by grant 10-092792/DSF from the Danish Council for Strategic 
Research, Programme Commission on Individuals, Disease and Society. 
G.H.G. is funded by an independent research scholarship from the Novo 
Nordisk Foundation.
AUTHOR CONTRIBUTIONS
P.R.H., K.E.K., H.-J.Z., and  J.S.M. wrote the manuscript. P.R.H., K.E.K., H-J.Z., 
G.H.G., and J.S.M. designed the research. P.R.H., K.E.K., H-J.Z., X.W., and 
J.S.M. performed the research. P.R.H., K.E.K., H-J.Z., X.W., G.H.G., C.T.-P., 
H.B.R., and J.S.M. analyzed the data.
CONFLICT OF INTEREST
The authors declared no conflict of interest.
© 2014 American Society for Clinical Pharmacology and Therapeutics
 1. Anderson, J.L. et al. ACC/AHA 2007 guidelines for the management of patients 
with unstable angina/non-ST-Elevation myocardial infarction: a report of 
the American College of Cardiology/American Heart Association Task Force 
on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines 
for the Management of Patients With Unstable Angina/Non-ST-Elevation 
Myocardial Infarction) developed in collaboration with the American College 
of Emergency Physicians, the Society for Cardiovascular Angiography 
and Interventions, and the Society of Thoracic Surgeons endorsed by the 
American Association of Cardiovascular and Pulmonary Rehabilitation 
and the Society for Academic Emergency Medicine. J. Am. Coll. Cardiol. 50, 
e1–e157 (2007).
 2. O’Gara, P.T. et al. ACCF/AHA 2013 guideline for the management of 
ST-elevation myocardial infarction: a report of the American College of 
Cardiology Foundation/American Heart Association Task Force on Practice 
Guidelines. J. Am. Coll. Cardiol. 61, e78–140.
 3. Ahmad, T., Voora, D. & Becker, R.C. The pharmacogenetics of antiplatelet 
agents: towards personalized therapy? Nat. Rev. Cardiol. 8, 560–571 (2011).
 4. Kazui, M. et al. Identification of the human cytochrome P450 enzymes 
involved in the two oxidative steps in the bioactivation of clopidogrel to its 
pharmacologically active metabolite. Drug Metab. Dispos. 38, 92–99 (2010).
 5. Hagihara, K. et al. A possible mechanism for the differences in efficiency and 
variability of active metabolite formation from thienopyridine antiplatelet 
agents, prasugrel and clopidogrel. Drug Metab. Dispos. 37, 2145–2152 (2009).
 6. Tang, M. et al. Antiplatelet agents aspirin and clopidogrel are hydrolyzed 
by distinct carboxylesterases, and clopidogrel is transesterificated in the 
presence of ethyl alcohol. J. Pharmacol. Exp. Ther. 319, 1467–1476 (2006).
 7. Zhu, H.J., Wang, X., Gawronski, B.E., Brinda, B.J., Angiolillo, D.J. & Markowitz, J.S. 
Carboxylesterase 1 as a determinant of clopidogrel metabolism and 
activation. J. Pharmacol. Exp. Ther. 344, 665–672 (2013).
 8. Bouman, H.J. et al. Paraoxonase-1 is a major determinant of clopidogrel 
efficacy. Nat. Med. 17, 110–116 (2011).
 9. Bates, E.R., Lau, W.C. & Angiolillo, D.J. Clopidogrel-drug interactions. J. Am. Coll. 
Cardiol. 57, 1251–1263 (2011).
 10. Olesen, J.B. et al. Calcium-channel blockers do not alter the clinical efficacy of 
clopidogrel after myocardial infarction: a nationwide cohort study. J. Am. Coll. 
Cardiol. 57, 409–417 (2011).
 11. Lewis, J.P. et al. The functional G143E variant of carboxylesterase 1 is 
associated with increased clopidogrel active metabolite levels and greater 
clopidogrel response. Pharmacogenet. Genomics 23, 1–8 (2013).
 12. Zhu, H.J., Appel, D.I., Johnson, J.A., Chavin, K.D. & Markowitz, J.S. Role of 
carboxylesterase 1 and impact of natural genetic variants on the hydrolysis of 
trandolapril. Biochem. Pharmacol. 77, 1266–1272 (2009).
 13. Thomsen, R., Rasmussen, H.B. & Linnet, K.; INDICES Consortium. In vitro drug 
metabolism by human carboxylesterase 1: focus on angiotensin-converting 
enzyme inhibitors. Drug Metab. Dispos. 42, 126–133 (2014).
 14. Satoh, T. & Hosokawa, M. Structure, function and regulation of 
carboxylesterases. Chem. Biol. Interact. 162, 195–211 (2006).
 15. Laizure, S.C., Herring, V., Hu, Z., Witbrodt, K. & Parker, R.B. The role of human 
carboxylesterases in drug metabolism: have we overlooked their importance? 
Pharmacotherapy 33, 210–222 (2013).
 16. Drummer, O.H., Nicolaci, J. & Iakovidis, D. Biliary excretion and conjugation of 
diacid angiotensin-converting enzyme inhibitors. J. Pharmacol. Exp. Ther. 252, 
1202–1206 (1990).
 17. Pang, K.S., Barker, F. 3rd, Cherry, W.F. & Goresky, C.A. Esterases for enalapril 
hydrolysis are concentrated in the perihepatic venous region of the rat liver. J. 
Pharmacol. Exp. Ther. 257, 294–301 (1991).
 18. Vistoli, G., Pedretti, A., Mazzolari, A. & Testa, B. In silico prediction of human 
carboxylesterase-1 (hCES1) metabolism combining docking analyses and MD 
simulations. Bioorg. Med. Chem. 18, 320–329 (2010).
 19. Vertes, V. & Haynie, R. Comparative pharmacokinetics of captopril, enalapril, 
and quinapril. Am. J. Cardiol. 69, 8C–16C (1992).
 20. Kuliczkowski, W. et al. Interindividual variability in the response to oral 
antiplatelet drugs: a position paper of the Working Group on antiplatelet 
drugs resistance appointed by the Section of Cardiovascular Interventions of 
the Polish Cardiac Society, endorsed by the Working Group on Thrombosis of 
the European Society of Cardiology. Eur. Heart J. 30, 426–435 (2009).
 21. Sibbing, D., Byrne, R.A., Bernlochner, I. & Kastrati, A. High platelet reactivity 
and clinical outcome - fact and fiction. Thromb. Haemost. 106, 191–202 (2011).
 22. Shuldiner, A.R. et al. Association of cytochrome P450 2C19 genotype with 
the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA 302, 
849–857 (2009).
 23. Frelinger, A.L. 3rd et al. Clopidogrel pharmacokinetics and pharmacodynamics 
vary widely despite exclusion or control of polymorphisms (CYP2C19, ABCB1, 
PON1), noncompliance, diet, smoking, co-medications (including proton 
pump inhibitors), and pre-existent variability in platelet function. J. Am. Coll. 
Cardiol. 61, 872–879 (2013).
 24. Angiolillo, D.J. et al. Impact of platelet reactivity on cardiovascular outcomes 
in patients with type 2 diabetes mellitus and coronary artery disease. J. Am. 
Coll. Cardiol. 50, 1541–1547 (2007).
 25. Angiolillo, D.J. et al. Randomized comparison of a high clopidogrel 
maintenance dose in patients with diabetes mellitus and coronary artery 
disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus 
(OPTIMUS) study. Circulation 115, 708–716 (2007).
ClInICAl phArMACology & ThErApEuTICS | VOLUME 96 NUMBER 6 | DECEMBER 2014 721
Articles
 26. Hosokawa, M. et al. Genomic structure and transcriptional regulation of the 
rat, mouse, and human carboxylesterase genes. Drug Metab. Rev. 39, 1–15 
(2007).
 27. Marsh, S. et al. Pharmacogenomic assessment of carboxylesterases 1 and 2. 
Genomics 84, 661–668 (2004).
 28. Zhu, H.J. et al. Two CES1 gene mutations lead to dysfunctional 
carboxylesterase 1 activity in man: clinical significance and molecular basis. 
Am. J. Hum. Genet. 82, 1241–1248 (2008).
 29. Fukami, T., Takahashi, S., Nakagawa, N., Maruichi, T., Nakajima, M. & Yokoi, T. In 
vitro evaluation of inhibitory effects of antidiabetic and antihyperlipidemic 
drugs on human carboxylesterase activities. Drug Metab. Dispos. 38, 
2173–2178 (2010).
 30. Takahashi, S., Katoh, M., Saitoh, T., Nakajima, M. & Yokoi, T. Different inhibitory 
effects in rat and human carboxylesterases. Drug Metab. Dispos. 37, 956–961 
(2009).
 31. Shi, D. et al. Anti-influenza prodrug oseltamivir is activated by 
carboxylesterase human carboxylesterase 1, and the activation is inhibited by 
antiplatelet agent clopidogrel. J. Pharmacol. Exp. Ther. 319, 1477–1484 (2006).
 32. Zhu, H.J., Appel, D.I., Peterson, Y.K., Wang, Z. & Markowitz, J.S. Identification 
of selected therapeutic agents as inhibitors of carboxylesterase 1: potential 
sources of metabolic drug interactions. Toxicology 270, 59–65 (2010).
 33. Floyd, C.N., Passacquale, G. & Ferro, A. Comparative pharmacokinetics and 
pharmacodynamics of platelet adenosine diphosphate receptor antagonists 
and their clinical implications. Clin. Pharmacokinet. 51, 429–442 (2012).
 34. Wiviott, S.D. et al.; TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in 
patients with acute coronary syndromes. N. Engl. J. Med. 357, 2001–2015 (2007).
 35. Cannon, C.P. et al.; PLATelet inhibition and patient Outcomes Investigators. 
Comparison of ticagrelor with clopidogrel in patients with a planned invasive 
strategy for acute coronary syndromes (PLATO): a randomised double-blind 
study. Lancet 375, 283–293 (2010).
 36. Takahashi, M., Pang, H., Kawabata, K., Farid, N.A. & Kurihara, A. Quantitative 
determination of clopidogrel active metabolite in human plasma by LC-MS/
MS. J. Pharm. Biomed. Anal. 48, 1219–1224 (2008).
 37. Tuffal, G. et al. An improved method for specific and quantitative 
determination of the clopidogrel active metabolite isomers in human plasma. 
Thromb. Haemost. 105, 696–705 (2011).
 38. Andersen, T.F., Madsen, M., Jørgensen, J., Mellemkjoer, L. & Olsen, J.H. The 
Danish National Hospital Register. A valuable source of data for modern 
health sciences. Dan. Med. Bull. 46, 263–268 (1999).
 39. Gaist, D., Sørensen, H.T. & Hallas, J. The Danish prescription registries. Dan. 
Med. Bull. 44, 445–448 (1997).
 40. Sørensen, R. et al. Initiation and persistence with clopidogrel treatment after 
acute myocardial infarction: a nationwide study. Br. J. Clin. Pharmacol. 66, 
875–884 (2008).
 41. Lamberts, M. et al. Bleeding after initiation of multiple antithrombotic drugs, 
including triple therapy, in atrial fibrillation patients following myocardial 
infarction and coronary intervention: a nationwide cohort study. Circulation 
126, 1185–1193 (2012).
 42. Cunningham, A., Stein, C.M., Chung, C.P., Daugherty, J.R., Smalley, W.E. 
& Ray, W.A. An automated database case definition for serious bleeding 
related to oral anticoagulant use. Pharmacoepidemiol. Drug Saf. 20, 
560–566 (2011).
 43. Madsen, M., Davidsen, M., Rasmussen, S., Abildstrom, S.Z. & Osler, M. The 
validity of the diagnosis of acute myocardial infarction in routine statistics: a 
comparison of mortality and hospital discharge data with the Danish MONICA 
registry. J. Clin. Epidemiol. 56, 124–130 (2003).
 44. Krarup, L.H., Boysen, G., Janjua, H., Prescott, E. & Truelsen, T. Validity of stroke 
diagnoses in a National Register of Patients. Neuroepidemiology 28, 150–154 
(2007).
 45. Tu, J.V., Austin, P.C., Walld, R., Roos, L., Agras, J. & McDonald, K.M. Development 
and validation of the Ontario acute myocardial infarction mortality prediction 
rules. J. Am. Coll. Cardiol. 37, 992–997 (2001).
 46. Rasmussen, S., Zwisler, A.D., Abildstrom, S.Z., Madsen, J.K. & Madsen, M. 
Hospital variation in mortality after first acute myocardial infarction in 
Denmark from 1995 to 2002: lower short-term and 1-year mortality in high-
volume and specialized hospitals. Med. Care 43, 970–978 (2005).
722 VOLUME 96 NUMBER 6 | DECEMBER 2014 | www.nature.com/cpt
